secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2024-09-17T23:59:59+00:00
Accession:  0000950170-24-107259
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics CCO James Hassard to depart effective October 14, 2024
----------------------------------------------------------------

- James Hassard separates as Chief Commercial Officer; last day October 14, 2024.
- Hassard will receive severance per Employment Agreement for termination without cause, subject to release.
- No replacement for CCO role announced by Crinetics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017024107259/0000950170-24-107259-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017024107259/crnx-20240913.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-107259

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer